Global Antisense & Rnai Therapeutics Industry: Key Statistics and Insights in 2025-2033

Summary:

• The global antisense & Rnai therapeutics market size reached USD 1.8 Billion in 2024.
• The market is expected to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.03% during 2025-2033.
• North America leads the market, accounting for the largest antisense & Rnai therapeutics market share.
• Antisense RNA makes up most of the market share in the technology segment because it provides better effectiveness.
• Pulmonary delivery holds the largest share in the antisense & Rnai therapeutics industry.
• The market has been classified into several categories based on the application: oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
• The primary driver of the antisense & Rnai therapeutics market is the rise in funding and collaborations.
• Advances in genomic research and the growing number of chronic and genetic diseases are changing the antisense & RNAi therapeutics market.

Industry Trends and Drivers:

• Increasing Funding and Collaborations:

The demand for antisense and RNAi drugs is rising. This is due to more funding and partnerships. As a result, the market outlook is positive. Now, pharmaceutical companies, biotech firms, and academic institutions are collaborating. They aim to speed up the development of RNA-based therapies by sharing resources and expertise. Rising funding from public and private sectors is spurring market growth. This includes venture capital and government grants. Moreover, there is a rise in the number of research and clinical trials for antisense and RNAi drugs. Major pharmaceutical companies are partnering with biotech firms to jointly develop new treatments. These collaborations speed up turning scientific breakthroughs into medicines. They improve the drug pipeline and the chances of their marketing.

• Rising Prevalence of Chronic and Genetic Diseases:

The increasing prevalence of chronic diseases, such as cancer, neurodegenerative disorders, and genetic conditions, is catalyzing the demand for antisense and Rnai therapeutics. Traditional treatment methods often fail to address the root genetic causes of these diseases, leading to a growing interest in therapies that can modulate gene expression. Antisense and Rnai therapeutics offer a novel approach by targeting disease at the molecular level, enabling more effective treatments for conditions like Huntington’s disease, amyotrophic lateral sclerosis (ALS), and cardiovascular diseases. The growing demand for targeted and gene-based therapies due to the aging global population and lifestyle-related disorders among individuals is positively influencing the market.              

• Advancements in Genomic Research:

Technologies like CRISPR and next-generation sequencing have enhanced scientists' understanding of gene function and mutation, enabling them to identify and target disease-causing genes more precisely. This is leading to the development of RNA-based therapies, which can selectively silence or modify gene expression to treat various diseases. The ability to design antisense oligonucleotides (ASOs) and Rnai molecules with greater specificity and fewer side effects is driving innovation in this field. Furthermore, technological advancements in gene-editing tools are supporting the integration of Rnai into broader therapeutic frameworks, expanding the range of treatable conditions. As research uncovers new therapeutic targets, the pipeline for RNA-based drugs is growing.

Grab a sample PDF of this report: https://www.imarcgroup.com/antisense-rnai-therapeutics-market/requestsample

Antisense & Rnai Therapeutics Market Report Segmentation:

Breakup By Technology:

• RNA Interference
  • siRNA
  • miRNA
• Antisense RNA

Antisense RNA accounts for the majority of shares as it offers enhanced effectiveness.

Breakup By Route of Administration:

• Intravenous Route
• Subcutaneous Route
• Intrathecal Route
• Pulmonary Delivery
• Intraperitoneal Injection
• Others

Pulmonary delivery dominates the market because of its ability to enable a high concentration of the solution.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position owing to a large market for antisense & Rnai therapeutics driven by favorable government initiatives.

Top Antisense & Rnai Therapeutics Market Leaders:

The antisense & Rnai therapeutics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Alnylam Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals Inc.
• Benitec Biopharma Ltd.
• Bio-Path Holdings Inc.
• Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
• Ionis Pharmaceuticals Inc.
• OliX Pharmaceuticals Inc.
• Phio Pharmaceuticals Corp.
• Sarepta Therapeutics Inc.
• Silence Therapeutics
• Sirnaomics Inc

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145